G. Stamper

发表

Structure of MurF from Streptococcus pneumoniae co‐crystallized with a small molecule inhibitor exhibits interdomain closure

P. Hajduk, K. Longenecker, V. Stoll, 2005, Protein Science.

Structure-activity relationships of novel potent MurF inhibitors.

David D. Anderson, P. Hajduk, R. Clark, 2004, Bioorganic & medicinal chemistry letters.

Structure‐based Optimization of MurF Inhibitors

David D. Anderson, P. Hajduk, K. Longenecker, 2006, Chemical biology & drug design.

Discovery of potent inhibitors of dihydroneopterin aldolase using CrystaLEAD high-throughput X-ray crystallographic screening and structure-directed lead optimization.

Jean M. Severin, Rolf Wagner, Vincent S Stoll, 2004, Journal of medicinal chemistry.

Discovery of 3H-benzo[4,5]thieno[3,2-d]pyrimidin-4-ones as potent, highly selective, and orally bioavailable inhibitors of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM) kinases.

V. Stoll, Eric F. Johnson, N. Soni, 2009, Journal of medicinal chemistry.

Accelerated Stability Testing of Proteins and Peptides: pH-Stability Profile of Insulinotropin Using Traditional Arrhenius and Non-Linear Fitting Analysis

G. Stamper, W. J. Lambert, 1995 .

A side reaction of alanine racemase: transamination of cycloserine.

D. Ringe, T. Fenn, A. Morollo, 2003, Biochemistry.

Development of an analytical reversed-phase high-performance liquid chromatography assay for transforming growth factor β3

G. Stamper, W. J. Lambert, 1995 .

Effect of a Y265F mutant on the transamination-based cycloserine inactivation of alanine racemase.

D. Ringe, T. Fenn, T. Holyoak, 2005, Biochemistry.